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Abstract: The natural history of human cytomegalovirus (HCMV) is inextricably associated 
with mucosal surfaces. The vast preponderance of primary infections occur following 
mucosal exposure to infectious virions, and the high seroprevalence of HCMV throughout 
the world is due to long-term excretion of HCMV in bodily fluids from multiple mucosal 
sites. Accumulating evidence presents a model where the earliest virus-host interactions 
following infection dictate the long-term pattern of infection, alter innate immune responses 
that skew adaptive responses to enable persistence within an immune host, and are essential 
for reinfection of a host with prior immunity. HCMV has evolved a complex repertoire of 
viral functions fine-tuned to manipulate the immune environment both locally at the sites of 
infection and systemically within an infected host. Collectively, viral immune modulation 
represents a significant impediment for an HCMV vaccine. As HCMV can disseminate 
beyond mucosal surfaces to reinfect immune hosts, it may not matter whether prior immunity 
results from prior infection or immunization. A better understanding of the earliest  
virus-hosts interactions at mucosal surfaces may identify elements of the viral proteome that 
are especially susceptible to vaccine-mediated disruption and prevent challenge virus from 
disseminating to distal sites, particularly the maternal-fetal interface. 
Keywords: cytomegalovirus; nonhuman primate; RhCMV; immune modulation; 
persistence; vaccine; reinfection 
 
OPEN ACCESS 
Viruses 2014, 6 1484 
 
 
1. Introduction 
Herpesviridae are a family of ubiquitous pathogens with ancient origins, dating back 400 million 
years, and they have co-evolved with their radiating host species since the progenitor herpes virus 
species arose [1]. The extent of co-evolution is such that herpes simplex virus (HSV-1) sequences have 
been used to track human global migration out of Africa [2]. If evolutionary longevity and the 
percentage of infected hosts measure the success of a pathogen, this family is very successful. While 
the classification of Herpesviridae is based on virion structure, all herpes viruses share the phenotype 
of establishing a lifelong persistence within the infected and, usually, immune-competent host. 
Mechanisms of persistence remain an active area of research into herpes virus natural histories. While 
large gaps in our knowledge of persistence remain to be filled, it is becoming clear that there are 
common themes amongst all herpes viruses layered onto virus-specific functions that modulate host 
cell signaling, trafficking, activation, antigen presentation, and lifespan. Based on our current 
understanding, some viral immune modulation mechanisms can be sub-grouped by family (alpha-, 
beta-, or gamma- herpesvirinae) or can be species-specific. One unifying feature of all herpes viruses 
is the central role of epithelial cells in the infectious cycle in mediating the initial portal of entry during 
infection of an individual in addition to serving as the exit site for secretion into bodily fluid to 
maintain the virus within the larger population of susceptible hosts. In between these points of the 
HCMV infectious cycle, herpes viruses disseminate to family-specific cell types of persistence for the 
alpha-, beta-, or gammaherpesvirinae, including neurons, CD34
+
 and other cell types, and B cells, 
respectively. It is highly likely that the raison d’être for sites of persistence is to provide a privileged 
site for viral genomes, resistant to immune-mediated clearance, that can occasionally or subliminally 
reactivate to produce infectious virions that can traffic back to mucosal epithelial cells and be secreted 
in bodily fluids. Analysis of the central role of mucosal epithelial cells in the life cycle of human 
cytomegalovirus (HCMV) illustrates the complexities and the challenges confronting development of 
HCMV vaccines designed to prevent primary infection and, hopefully, reinfection of those with 
preexisting HCMV immunity. 
2. HCMV Natural History 
2.1. HCMV Shedding in Bodily Fluids 
HCMV is the prototypical betaherpesvirus with a complex natural history, a large and incompletely 
defined genetic coding capacity, and a seemingly contradictory virus-host relationship. HCMV is 
ubiquitous throughout the world, and seroprevalence rates range from ~50% in the U.S. to close  
to 100% in some developing countries [3]. Primary HCMV infection in immune-competent individuals 
is generally associated with either transient and mild clinical outcomes or inapparent seroconversion. 
Based on the reported rate of congenital infection (~0.7%), primary infections result almost 
exclusively following mucosal exposure to horizontally transmitted virions in bodily fluids. Despite 
mucosal epithelia serving as the entry point for the preponderance of HCMV infections, there is 
virtually nothing known about the virological and immunological cascade of events within the mucosa 
and submucosa. 
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Like all herpes viruses, HCMV establishes a lifelong persistence characterized by the presence of 
cells harboring latent viral genomes that periodically reactivate to produce infectious virions. The 
frequency of shedding varies dependent in part on age, health, the particular bodily fluid, and 
physiologic status. In children under the age of five years infected congenitally or within the first years 
of birth, the frequency of HCMV in saliva and/or urine has been reported as high as 80% with rates 
declining as the children age (12%–23%) [4,5]. In healthy non-human immunodeficiency virus  
(HIV)-infected adults, cross-section surveys of HCMV excretion in cervical swabs, saliva, and/or urine 
indicate rates of detection between 7%–24%, with higher rates observed in the context of HIV 
coinfection (non-HAART treated) or sexually transmitted diseases [4,6–9]. Longitudinal studies of 
seroimmune healthy women demonstrate that 83% exhibited at least one positive urine sample with 
HCMV [8]. Rates of HCMV reactivation during pregnancy lead to the conclusion that HCMV is 
exquisitely suited for shedding in breast milk. Three studies have observed frequencies of HCMV 
detection in breast milk from 89%–100% [10–12]. While it is well established that HCMV can 
establish near complete latency in certain cell types (e.g., CD34
+
 myeloid progenitor cells), 
characterized by an extremely limited pattern of HCMV transcripts [13–18], long-term shedding in 
mucosal fluids is the norm during persistent infection. Even more pronounced than primary infection, 
persistent HCMV shedding is not associated with disease in those infected individuals with functional 
immune systems. As with the large gaps in our knowledge of initial virus-host interactions at mucosal 
surfaces during primary infection, the mechanistic basis for the frequency and magnitude of mucosal 
shedding are virtually unexplored for HCMV. 
2.2. HCMV Immune Responses 
The general absence of HCMV clinical sequelae associated with primary infection and the almost 
complete absence during persistent infection emphasize the protective nature of host antiviral immune 
responses. Primary HCMV infection stimulates robust immune responses, including broadly 
neutralizing antibodies to multiple envelope glycoproteins [19–21] and especially prominent antiviral 
T cell responses [22,23]. The protective efficacy of these immune responses is emphasized by the fact 
that declines in functional immunity, either by iatrogenic immunosuppression or immune deficiency, is 
associated with significantly increased risks of HCMV morbidity and mortality. Similarly, congenital 
HCMV infection is a leading infectious cause of hearing loss and developmental disorders in infants in 
the U.S. [21,24]. Primary HCMV infection in the mother puts the infant at greater risk of symptomatic 
disease [19]. Likewise, the immunological immaturity of fetuses portends increased risk of 
developmental deficits following congenital HCMV infection (reviewed in [25]). Due to the severe 
diseases that HCMV can cause in people with limited functional immunity, an HCMV vaccine has 
been a public health priority for the past several decades [24,26–30]. An overriding theme of HCMV 
vaccine development has been to recapitulate through vaccination the dominant immune responses 
generated during primary infection. 
A potential limitation of this approach is that peripheral immune responses (e.g., neutralizing 
antibodies, antigen-specific T cells) constitute the vast majority of immune responses analyzed in 
infected individuals. While informative, limitation of immune responses to the periphery may result in 
failure to identify critical tissue-specific immune responses. In particular, mucosal immune responses 
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in situ, including innate responses, to HCMV are notably understudied relative to peripheral B and T 
cell responses. A limited number of studies have detected very low but detectable binding and/or 
neutralizing antibody responses to HCMV in saliva following either natural infection and, importantly, 
immunization with live attenuated virus or recombinant gB subunit vaccination [31–33]. Saliva 
antibody responses, which are not detectable in all those with serum antibodies to HCMV, include 
IgG, IgA, and sIgA. Neutralizing antibodies have differentially been associated with the IgA and  
IgG fractions. 
Three features of these studies that may be relevant to vaccine design include the following.  
(1) Vaccination can lead to detectable increases in saliva antibodies [33]; (2) Saliva IgG titers are a 
fraction of serum antibody IgG titers but generally correlate with peripheral IgG [31,33]; (3) There is 
no apparent association between cessation of HCMV shedding in saliva of young HCMV-infected 
children and development of detectable neutralizing antibodies in saliva [32]. As mucosal surfaces 
represent the first line of defense against HCMV infection, it stands to reason that a more thorough 
understanding of the earliest host-pathogen interactions at mucosal surfaces is critical for the future 
development of vaccine strategies designed to disrupt the natural pattern of infection, persistence, and 
shedding. Enhancement of innate immune responses at the site of infection might tip the balance in 
favor of the host and allow for viral clearance or reduced viral shedding from mucosal surfaces later in 
the replication cycle. 
2.3. HCMV Persistence 
The preceding discussion about the mostly protective immune responses resulting from primary 
infection presents something of a conundrum about the quality of the antiviral immune responses. Like 
all herpes viruses, HCMV persists for the lifetime of immune-competent hosts, and the longitudinal 
shedding of virus in bodily fluids demonstrates that viral gene expression occurs in the presence of the 
very same immune responses that protect against viral sequelae. Simply put, HCMV stimulates 
immune responses that effectively limit infection and mostly protect the host from disease, yet are 
insufficient to clear persistent reservoirs of infected cells. The chronicity of antiviral immunity 
following primary infection strongly implies chronic viral gene expression at a level sufficient to 
maintain antibody and T cell responses [23]. There is no solid evidence that lifelong HCMV infection 
and gene expression result in overt HCMV pathology, which leads to the conclusion that HCMV has 
evolved a lifecycle to maximize its potential to excrete infectious virions that can disseminate to 
susceptible hosts. Beyond the potential for spreading virus horizontally and vertically, there are 
numerous reports in the last several years suggesting that chronic HCMV infection may be associated 
with increased risk of some age-related diseases. It should be stressed, however, that the linkages are 
statistical associations without conclusive proof of HCMV causality [24,34]. It may turn out that, as 
human lifespan increases well beyond historic levels, chronic HCMV infection may have adverse 
effects in the context of an aging immune system. 
2.4. HCMV Reinfection 
Another aspect of the restricted immune protection conferred by primary infection is the failure of 
preexisting immunity to fully protect from reinfection with a different strain of HCMV [21,35,36]. 
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Multiple studies have documented that HCMV can reinfect individuals with prior HCMV  
immunity [8,21,37–43]. Congenital infection rates of 1% have been reported in populations with 100% 
seroprevalence of HCMV. The demonstration that seropositive women who give birth to a congenitally 
infected infant acquired new antigenic reactivity to HCMV antigens between pregnancies is strong 
evidence that prior immunity is incompletely protective against reinfection with antigenic HCMV 
variants. This is particularly remarkable because, in healthy long-term HCMV carriers, ~10% of 
memory T cells are HCMV-specific, and neutralizing antibodies are generated against multiple viral 
glycoproteins including gB [23,44–48]. In another study, 30% of seropositive women that were 
longitudinally evaluated developed novel HCMV antibody specificities, equivalent to an annual rate of 
HCMV reinfection of 10% [49]. Studies of reinfection indicate a viral mechanism to surmount 
preexisting immune memory to initiate a new infection, leading to the clinical ramification that 
infection of an immune host is probably independent of whether prior immunity is from prior infection 
or prior vaccination. The reinfection studies also suggest that the true disease burden might be 
underestimated, particularly so since the reinfection studies to date are based on looking at an 
extremely limited number of epitope variants. 
2.5. HCMV Immune Modulation 
The ability of HCMV to persist in an immune-competent host and reinfect immune individuals is 
undoubtedly related to the extraordinary devotion of HCMV coding content to viral proteins that 
modulate host immune cell function. Based on the number of open reading frames that can be deleted 
without impairing replication in fibroblasts, it is likely that ~50% of viral ORF are involved in an 
extensive repertoire of immune modulating functions [50,51]. Given the protracted evolution of herpes 
viruses, in general, and HCMV, in particular, it is highly likely that evolution of viral functions that 
modulate innate and adaptive immunity define the mechanistic basis for the phenotypic features that 
define HCMV as the virus that it is. Consistent with this interpretation, it is, perhaps, noteworthy that 
there have been no descriptions of immune escape variants arising during subclinical persistent 
infections, or fulminant outcomes associated with immunosuppression or immunodeficiency. In 
contrast, drug-resistant variants readily arise after initiation of anti-HCMV chemotherapies [52], 
which, based on recent estimates of sequence variation occurring during HCMV infection, should 
come as no surprise [53]. One interpretation of these discordant responses to immune-mediated and 
antiviral-mediated selective pressures might be the result of the protracted evolution of herpes viruses 
in hosts possessing innate and adaptive immune systems. HCMV evolved the broad repertoire of 
immunomodulatory functions that presumably confers a selective advantage over genetic drift as a 
means to persist within a host and disseminate throughout the population. In contrast, anti-HCMV 
chemotherapies are very recent treatment modalities, and therefore, there are no apparent HCMV-encoded 
functions that can directly counteract the different anti-HCMV drugs in clinical use. 
2.6. Future Directions for HCMV Vaccine Development 
One of the earliest calls for development of an HCMV vaccine stemmed from the clinical recognition 
of the grave infectious threat that intrauterine HCMV represents to fetal growth and development [27]. 
Based on his 15-year retrospective analysis of congenital HCMV cases, Hanshaw concluded that,  
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“… any thoughtful program aimed at prevention or treatment deserves consideration”. Multiple lines 
of reasoning, focusing on (1) lifelong viral gene expression and shedding; (2) the magnitude of host 
cell immune responses required to prevent sequelae; and (3) reinfection of immune hosts, lead to the 
argument that HCMV is unlike any other virus for which vaccines have been clinically approved. 
Accordingly, “any thoughtful program aimed at prevention” of HCMV infection is likely to require 
adjuncts to the current paradigm of preventing attachment of HCMV virions to susceptible cells by  
gB-mediated neutralization. There are numerous challenges confronting HCMV vaccine development 
including a complex natural history, incompletely defined correlates of immune protection, and 
financial and logistical challenges in sufficiently powered clinical trials. Recent studies using the 
rhesus macaque model of HCMV demonstrate that infection of rhesus macaques with rhesus CMV 
(RhCMV) offers novel insight into vaccine strategies that have clinical relevance for development of 
HCMV vaccines. The remainder of this review will focus on the mechanisms of RhCMV infection, 
transmission, persistence, and reinfection and how the results of these studies inform new HCMV 
vaccine modalities. 
3. RhCMV Natural History 
3.1. Endemic RhCMV Infectious Cycle in Rhesus Macaques (Macaca mulatta) 
Development of the RhCMV model of HCMV persistence and pathogenesis has benefitted by 
characterization of RhCMV natural history in large breeding cohorts to establish normative parameters 
of endemic infections to guide experimental studies. One unifying element of population studies is the 
central role of mucosal surfaces in the infectious cycle of RhCMV. Studies have demonstrated that the 
kinetics of RhCMV dissemination throughout mixed cohorts of uninfected and infected animals is a 
function of the persistent shedding of virus in bodily fluids of infected animals and the repeated 
mucosal exposure of uninfected animals to virus. RhCMV is endemic in breeding cohorts of rhesus 
macaques, as well as in native populations of wild macaques, and almost 100% of naive animals 
seroconvert by one year of age, well before the onset of sexual maturity around four years of age [54–57]. 
There are no known clinical sequelae associated with primary RhCMV infection in immune competent 
animals, which stands in contrast to the severe pathogenic outcomes following SIV immunodeficiency 
[58–60] or iatrogenic immunosuppression [56]. Seroconversion of previously naïve animals is often, 
but not always, contemporaneous with the detection by TaqMan real-time PCR of low quantities of 
RhCMV genomes in plasma [61,62]. The quantities of viral DNA detected in plasma are lower than 
those detected in saliva later in infection, consistent with hematogenous spread of progeny virions 
from local portals of entry to distal sites throughout the body. Like HCMV, RhCMV can be detected in 
multiple cell types throughout the body [58,60], and the virus efficiently seeds those anatomic sites 
where virus can be shed. 
Recapitulating the virus-host relationship for HCMV, RhCMV persists, and chronic RhCMV gene 
expression is the norm during the life of the infected animal, despite the presence of neutralizing 
antibody and T cell responses [63–65]. Key sites of persistence include the salivary glands and 
genitourinary tract. Infected animals can persistently and asymptomatically shed virus in bodily fluids 
(e.g., saliva and urine), often in high quantities, for years after primary infection [66–69]. Multiple 
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genetic variants have been detected in fluids of naturally infected animals [69–71], although there are 
no reports of deep sequencing to quantify the extent of sequence diversity. Because of persistent 
shedding in bodily fluids and the social dynamics of large macaque cohorts, RhCMV rapidly spreads 
through the cohort. In fact, RhCMV has an exceedingly high force of infection in naïve hosts. Two 
studies of mixed cohorts of infected and uninfected macaques demonstrate that the doubling rate of 
seroconversion of uninfected animals is five to nine weeks [54,61]. 
There have been no reports to date of vertical transmission of RhCMV, possibly due to the 
universal seroprevalence of RhCMV in breeding age female macaques [56]. Consequently, the high 
seroprevalence of RhCMV in large cohort is the direct consequence of repeated mucosal exposure of 
uninfected animals to horizontally transmitted virions in bodily fluids of infected animals. As such, 
this aspect of RhCMV natural history reflects the challenges that confront HCMV vaccine trials, 
namely repeated close contact of vaccinated/uninfected women to those shedding potentially 
antigenically variant HCMV in bodily fluids. One implication from the studies of RhCMV in mixed 
populations is that there are at least two strategies to minimize the risk of primary infection:  
(1) vaccinate those at-risk for primary infection; and (2) vaccinate those who may become the source 
of horizontally transmitted virus to minimize the potential for shedding of virus in bodily fluids (such 
as young children). While detailed molecular and virological investigations of RhCMV infection 
following natural exposure have not been reported, experimental data regarding cellular tropism and 
the virally encoded genes that are essential in this process provide insights into parts of the viral 
proteome that may be especially susceptible to vaccine-mediated disruption. 
3.2. Early Virus-Host Interactions during Experimental Infection 
Early virus-host interactions within the mucosa following natural exposure to RhCMV have not yet 
been explored. However, several studies using experimental inoculation via subcutaneous (SC) 
delivery of virus have revealed a salient aspect about early virus-host interactions relevant to HCMV 
vaccine design. In particular, the acute virus-host interactions following SC inoculation determine the 
long-term patterns of RhCMV infection. 
Several strains of RhCMV have been described in the literature, and strain-specific differences 
depend on the extent of fibroblast adaptation. RhCMV strain 68-1 is the prototypical strain that was 
isolated after co-culture of urine from a rhesus macaque on human fibroblasts [66,67]. Sequence 
analysis of the 68-1 genome after serial passage in human and/or rhesus fibroblasts revealed that the 
UL/b’ region of the genome had undergone rearrangements and loss of coding capacity, in particular 
RhUL128, RhUL130, and three CXC chemokine-like ORF [69,72]. Based on precedence with the 
HCMV gH-based pentamer [73,74], the loss of RhUL128 and RhUL130 results in severe attenuation 
of RhCMV tropism for epithelial and some endothelial cells in culture [75,76]. RhCMV strains 
UCD52 and UCD59 were also isolated initially on human and macaque fibroblasts, and subsequently 
passed exclusively on primary monkey kidney epithelial cells [61,77]. Sequence analyses of both 
UCD52 and UCD59 demonstrated that the UL/b’ regions of both strains retain the full coding capacity 
of wild-type RhCMV (i.e., never passed in culture) [69], and both retain epithelial cell tropism in vitro. 
Of particular note for vaccine strategies, strain-specific differences in the UL/b’ coding content result 
in distinct phenotypes of acute infection in vivo following SC inoculation. 
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Skin biopsies of the SC inoculation site obtained seven days after infection with either UCD52 or 
UCD59 are noted for prominent neutrophilic infiltration with extensive infection of endothelial cells 
(CD31-positive), fibroblasts (vimentin-positive), and macrophages (CD68-positive) [60]. In contrast, 
biopsies from animals infected seven days prior with 68-1 were noted for a predominant mononuclear 
cell infiltrate, and infected cells were predominantly fibroblasts and a reduced infection frequency in 
macrophages was observed (compared to UCD52/UCD59). Notably, no endothelial cells infected  
with 68-1 were detected (infection of epithelial cells was not evaluated in this study). This study 
confirmed that the expanded tropism conferred by the gH-anchored pentamer (in UCD52 and UCD59) 
observed in vitro is also observed in vivo. In addition, investigation of the earliest virus-hosts 
interactions highlights how RhCMV acutely alters local innate host responses, presumably due to the 
presence (UCD52/UCD59) or absence (68-1) of viral CXC chemokine-like ORF. As will be discussed 
below (Sections 3.3 and 3.4), differences in UL/b’ coding capacity also result in distinct long-term 
parameters of RhCMV infection. 
3.3. Rapid Emergence of RhCMV Variants with Complete UL/b’ Coding Capacity during 
Experimental Infection 
The strong positive selective pressures conferred by a full complement of UL/b’ coding capacity 
was recently described in a serendipitous finding with another annotated strain of RhCMV [78]. 
RhCMV strain 180.92 was isolated from a simian immunodeficiency virus (SIV)-infected monkey and 
serially passed on human and monkey fibroblasts without plaque purification [79]. Sequence analysis 
of overlapping cosmid clones generated from cells infected with the 180.92 stock revealed a large 
rearrangement in UL/b’ that resulted in the deletion of most of UL/b’-encoded ORF, compared to 68-1 
and wild-type RhCMV, but left intact the RhUL128-131 coding regions. RhCMV 180.92 exhibits 
greater epithelial/endothelial cell tropism than 68-1, consistent with retention and expression of the 
complete gH-anchored pentamer in 180.92, although the ability to infect epithelial/endothelial cells is 
reduced compared to a repaired version of 68-1 (BRh68-1.2) in which the RhUL128 and RhUL130 
genes were engineered back into 68-1 [75]. Reduced growth of 180.92 in epithelial/endothelial cells 
compared to BRh68-1.2, is likely due to other UL/b’ ORF distinct from RhUL128-131. Stocks of 
RhCMV 180.92 were prepared from bulk infected cell cultures, and plaque purification was never 
done during serial passage. PCR analysis of the 180.92 stock subsequently revealed the presence of a 
minor sequence variant comprising <15% of the total RhCMV genomes within the 180.92 stock. PCR 
amplification and sequencing of molecular clones determined that the minor sequence variant was, in 
fact, a full-length RhCMV genome, presumably representing the remnant of the original unrearranged 
genome prior to fibroblast adaptation. Reexamination of tissues from these animals and other animals 
unexpectedly revealed that there was a rapid emergence of the full-length variant despite it being a 
minor constituent in the virus stock [78]. 
Six RhCMV uninfected macaques, including one that was SIV-infected, were inoculated 
intravenously with the RhCMV 180.92 stock, and longitudinal plasma, saliva, and urine samples were 
collected and analyzed for RhCMV. Using primer sets that distinguished the truncated and full-length 
genomic variants, it became apparent that the full-length variant rapidly became the dominant genomic 
form (>95%) in blood by three weeks post inoculation. Analysis of RhCMV in the tissues from the 
Viruses 2014, 6 1491 
 
 
SIV/RhCMV coinfected animal similarly demonstrated high-level genome copy numbers of the  
full-length in tissues. In contrast, the truncated genomic variant exhibited significantly lower genome 
copy numbers in plasma, tissues, urine, and saliva. These data demonstrate that the truncated 180.92 
variant is severely attenuated in vivo, despite the presence of the RhUL128-131 ORF. The results 
emphasize that additional UL/b’ ORF are essential for optimal replication and dissemination of 
RhCMV in vivo, and accordingly, these particular viral proteins represent potential vaccine targets to 
minimize hematogenous spread to tissues throughout the body. 
3.4. Long-term Parameters of RhCMV Infection during Experimental Infection 
The preceding rationale about vaccine-mediated targeting those UL/b’ ORF outside of RhUL128-131 
can also be applied to RhUL128-131, based on differences in long-term infections of variants 
containing or lacking RhUL128-131. In addition to an apparent defect in cell tropism during acute 
infection (described above), 68-1 is significantly attenuated for shedding in bodily fluids [60,61]. 
Uninfected animals inoculated SC with UCD52 and UCD59 are noted for persistent detection of 
RhCMV in the saliva and urine of most animals (~75%) beginning six to eight weeks after inoculation 
[61]. The prolonged detection of RhCMV following experimental inoculation reflects the pattern of 
RhCMV shedding in animals naturally exposed to RhCMV [66–68]. In marked contrast, 68-1 DNA is 
either below the limit of PCR detection, or infrequently detected at low copy numbers in either bodily 
fluid [80–82]. All of these studies used PCR detection of RhCMV DNA as a surrogate for virus 
isolation to assess virus shedding. As a measure of the biological relevance of PCR detection, animals 
inoculated with UCD52 or UCD59 can transmit virus to uninfected cage-mates, whereas horizontal 
transmission of 68-1 has not been observed [61]. This finding is particularly relevant for vaccine 
development strategies aimed at reducing viral shedding as a means to control horizontal infection. 
Together, these observations suggest impaired dissemination and shedding of 68-1 in vivo and 
demonstrate the essential nature of mucosal tissues in CMV infection and the requirement for broad 
cellular tropism. It should be noted that RhCMV 68-1 is not replication impaired in vivo due to the 
absence of a functional gH-anchored pentamer and the CXC-chemokine-like ORF. The pattern of acute 
infection with 68-1 (described in Section 3.2) [60] demonstrates that 68-1 can utilize, presumably,  
gB-mediated entry into permissive cells, and 68-1 can disseminate throughout the body [83]. 
Moreover, studies using RhCMV 68-1 as a vaccine vector to express SIV antigens have observed some 
excretion of the engineered 68-1 vectors in urine of inoculated animals [22,84]. 
Although the mechanisms involved in mucosal transmission are poorly understood, disruption of 
the natural pattern of mucosal shedding through vaccination, by either reducing the incidence of 
shedding in infected people or enhancing mucosal immune responses to prevent infection or 
reinfection, is a novel strategy that is supported by recent observations in macaques. A better 
understanding of the early interactions between RhCMV and its host, and the mucosal immune 
responses involved in RhCMV infection, are essential for this vaccine development strategy. 
 
3.5. RhCMV Immune Modulation 
It is an accepted precept of vaccinology that the quality and quantity of adaptive immune responses 
are dependent on the quality and quantity of innate responses [85]. Accordingly, there is increasing 
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effort in designing adjuvants that direct adaptive immunity in a direction that increase protective 
efficacy. Acute differences in innate immune responses at sites of inoculation following SC exposure 
to either UCD52/UCD59 or 68-1 (described above) [60] imply that RhCMV (and by extension 
HCMV) similarly exerts an adjuvant-like effect on the local innate effector cells to direct adaptive 
immune responses towards a situation that favors viral persistence at the expense of immune-mediated 
clearance of RhCMV-infected cells. The RhCMV functions that presumably mediated the relative 
differences in the nature of the inflammatory response (polymorphonuclear cells for UCD52/UCD59 
and mononuclear cells for 68-1) is due to the presence of the CXC-like ORF in UCD52/UCD59, 
although no functional activity for these ORF has been reported [69]. The concept that a critical step in 
early RhCMV-host interactions involves rapid manipulation of innate responses is bolstered by studies 
investigating the role of the virally encoded interleukin-10 like protein of RhCMV. 
Primate CMVs, with the exception of chimpanzee CMV, encode a viral IL-10 gene that is an 
evolutionary remnant of a transduced cellular IL-10 (cIL-10) gene by a progenitor primate CMV at 
some point after the split of rodents and primates [56,86,87]. Despite extensive genetic drift of the 
HCMV and RhCMV viral IL-10 proteins (cmvIL-10 and rhcmvIL-10, respectively) from the cIL-10 
proteins of their respective hosts, these viral orthologs retain high affinity for the cognate cIL-10 
receptor [50] and nearly identical immunosuppressive properties in vitro to those exhibited by  
cIL-10 [56,87]. The conservation of functionality of cmvIL-10 and rhcmvIL-10 to that of cIL-10 leads 
to the proposition that expression of an IL-10-like protein in the context of viral infection suppresses 
acute immune responses to viral infection. 
The role of rhcmvIL-10 in primary infection was analyzed in macaques following SC inoculation 
with 68-1 or a 68-1 rhcmvIL-10 knockout virus (68-1ΔIL-10) [81]. Tissue biopsies taken from animals 
seven days after inoculation with 68-1 had markedly reduced cellularity at the inoculation site, but 
greater numbers of tissue macrophages, than 68-1ΔIL-10 inoculated animals [81]. In addition, there 
were fewer myeloid dendritic cells and decreased priming of naïve CD4
+
 T cells in the draining lymph 
nodes of 68-1 infected animals versus 68-1ΔIL-10 infected animals. Animals inoculated with 68-1 also 
showed impaired RhCMV-specific IgG responses and lower IgG avidity, compared with 68-1ΔIL-10 
infected animals. In sum, the functional absence of rhcmvIL-10 in 68-1ΔIL-10 resulted in increased 
innate immune recognition of viral antigens and increased adaptive immune responses. These results 
lead to a model whereby a critical step in RhCMV infection is the immediate manipulation of the local 
immune environment mediated, in part, by rhcmvIL-10. Based on this premise, secreted proteins, such 
as rhcmvIL-10, should represent reasonable vaccine targets to induce, particularly, antibodies that 
neutralize their function. 
A recent survey of RhCMV-infected macaques revealed that one consequence of the extensive 
genetic drift of rhcmvIL-10 from the cIL-10 protein of its host is that what was once a self-protein 
soon after transduction of the cIL-10 gene has become highly immunogenic in the context of viral 
infection [88]. All RhCMV-infected animals develop high avidity binding antibodies to rhcmvIL-10, 
and almost 100% of the animals also exhibit some level of antibodies that neutralize rhcmvIL-10 
function in bioassays. Importantly, the rhcmvIL-10-specific neutralizing antibody responses generated 
in these macaques did not cross-react with cIL-10. The cmvIL-10 protein is also immunogenic in 
HCMV-infected humans [89]. Together, these data provide proof-of-concept for targeting viral IL-10, 
an immune modulator, as a vaccine strategy to interrupt viral persistence. 
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To accomplish antigenic stimulation without triggering the cIL-10 receptor, a non-functional 
rhcmvIL-10 has been designed, cloned into an expression cassette, expressed, and purified [90]. 
Immunization of naïve macaques with a DNA prime/protein boost immunization strategy stimulated 
antibody responses that neutralized wild-type rhcmvIL-10 function without cross-neutralization of 
rhesus cIL-10 [90]. SC challenge of vaccinated animals with UCD59 resulted in significantly lower 
frequencies and loads of RhCMV DNA in plasma, saliva, and urine, compared to mock-vaccinated 
control animals [91]. These data are unprecedented for CMV vaccine strategies in that targeting a 
single viral immune modulator (i.e., rhcmvIL-10) elicited immune-mediated protection against viral 
challenge without inducing antibodies that neutralized RhCMV infection of cells. Given the large 
devotion of the HCMV coding capacity to immune modulating proteins (discussed in Section 2.5), the 
results targeting rhcmvIL-10 offer a compelling rationale to explore additional viral antigens involved 
in immune modulation. 
3.6. RhCMV Reinfection 
A considerable challenge to reducing congenital infection is the ability of HCMV to reinfect 
women with pre-conceptional immunity and subsequently cross the maternal-fetal interface (discussed 
in Section 2.4). The challenge arises because the mechanism for reinfection is unknown and, consequently, 
there are no prevention strategies short of absolutely minimizing exposure to virus shedding contacts. 
Fortunately, a study of RhCMV sheds light on viral mechanisms to overcome prior immunity. 
Evidence for RhCMV infection of immune competent hosts is suggestive from natural history 
studies but incontrovertible from experimental studies. As described above (Section 3.1), multiple 
genetic variants of RhCMV have been amplified by PCR from RhCMV-immune animals. While these 
reports are consistent with reinfection, given the repeated exposure to infectious virus in bodily fluids 
of infected cohorts, it cannot be ruled out that the animal, from which saliva samples were analyzed, 
was not infected with more than one variant during primary exposure to RhCMV. In contrast, 
experimental inoculation of immune animals with genetically tagged variants of RhCMV is 
exceedingly efficient. Engineered variants of RhCMV 68-1 that express the SIV proteins (gag, retanef) 
have been used to reinfect RhCMV immune animals [84]. Animals inoculated with the RhCMV vector 
expressing the SIV protein uniformly develop SIV protein-specific T cells responses, and the 
RhCMV/SIV vector can be recovered in the urine of reinfected animals. Reinfection can be observed 
following inoculation with as little as 100 PFU, highlighting the ability of RhCMV to overcome 
existing antiviral immune responses [22]. 
Based on this, Hansen et al. reasoned that an essential step in reinfection is overcoming “an initial 
immunological checkpoint”, and they addressed whether the RHCMV orthologs of the HCMV proteins 
disrupting MHC-I antigen presentation mediate RhCMV reinfection (US2, 3, 6, and 11) [22]. 
Engineered deletion of the RhUS2-11 genes did not impair the ability of the deletant variant to 
replicate in cultured fibroblasts, compared to the unmodified parental vector. RhCMVΔUS2-11 
expressing SIV gag was also able to establish infection in RhCMV-uninfected macaques, as 
demonstrated by recovery of RhCMVΔUS2-11 in the urine of infected animals and development of 
RhCMV-specific and gag-specific T cell responses. Notably, RhCMVΔUS2-11 was incapable of 
reinfecting RhCMV-immune animals following SC inoculation with 10
7
 PFU. These results 
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demonstrate that manipulation of the host immunity is essential for reinfection, and, together with 
studies of acute RhCMV infection, illustrate the role RhCMV immune modulating proteins play in the 
infectious cycle of RhCMV in vivo. 
4. Conclusions 
The results of the Phase II gB vaccine trial [29] represents an important step towards meeting the 
clarion call of Hanshaw to develop a vaccine that protects against the devastating consequences of 
intrauterine HCMV infection [27]. This clinical trial now represents the “gold standard” against which 
subsequent HCMV vaccine trials will be compared, and yet, it is not certain at this time whether the 
level of observed protection compels a Phase III trial. Key issues about how best to move forward 
include (1) optimization of gB immunization to induce greater protective neutralizing responses;  
(2) inclusion of additional envelope glycoproteins to induce broader neutralizing responses against 
other virologically relevant cell types (i.e., gH pentamer-mediated infection of epithelial and 
endothelial cells); and/or (3) targeting other parts of the HCMV proteome not involved in 
attachment/entry of susceptible cells. The vaccine potential for broadening neutralizing antibody 
responses beyond gB has been demonstrated recently by restoring the gH pentameric complex in the 
AD169 vaccine strain of HCMV [92,93]. While still in an early developmental stage, this strategy may 
help to address the difficult problem of the broad cellular tropism of HCMV. HCMV persistence in 
immune competent hosts and, in particular, the ability of HCMV to reinfect immune individuals leads 
to the proposition that HCMV is unlike most every other virus for which protective vaccines have been 
developed. Varicella zoster virus (VZV), an alphaherpesvirus and the only herpes virus for which there 
is a commercially available vaccine, persists in the infected host in a truly latent state, and recurrent 
disease is the result of reactivation of this latent virus after host immune responses have waned or 
become impaired. The attenuated VZV vaccine strain, Oka, was generated via serial passage in cell 
culture of a clinical VZV isolate. Similar strategies for HCMV have failed to generate a successful 
vaccine candidate (e.g., Towne) [94,95]. In addition, prior immunity to HCMV does not protect from 
reinfection despite robust adaptive immune responses. The ability to overcome extant neutralizing 
antibody responses and extraordinarily large HCMV-specific T cell responses emphasize the 
unprecedented role of HCMV-encoded immune modulating functions in HCMV natural history. Given 
the expense involved in conducting sufficiently powered clinical Phase II and Phase III trials, there is 
an essential need for rigorous pre-clinical studies that can inform which vaccine modalities should 
advance to human testing. 
Recent studies of RhCMV point to multiple ORF that can be targeted to change the course of acute 
infection, dissemination via the blood to tissues throughout the body, and the ability to seed distal sites 
where progeny virions are shed into bodily fluids. These antigens include: gB, pp65, the gH-pentamer 
complex, CXC chemokines, rhcmvIL-10, and other ORF in UL/b’ besides RhUL128-131. However, 
multiple RhCMV vaccine studies using a variety of antigen delivery modalities have demonstrated 
partial protection, at best, and the results are consistent with the complexities of HCMV vaccine 
design. It should be stressed that all RhCMV vaccine studies, and to our knowledge all animal vaccine 
models of HCMV vaccines, use direct parenteral introduction of challenge virus. This bypasses the 
potential for mucosal immunity in the vaccinee to control primary viral challenge, and subsequent 
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studies in animal models should work to recapitulate the repeated mucosal exposures to HCMV that 
vaccinees will encounter. 
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